Mechanism-based Predictions of Interactions

Franz Oesch, Barbara Oesch-Bartlomowicz, Jürgen Arens, Fred Fähndrich, Elke Vogel, Thomas Friedberg, and Hansruedi Glatt

1Institute of Toxicology, University of Mainz, Mainz, Germany; 2Department of Surgery, University of Kiel, Kiel, Germany

Exposure to more than one toxic compound is common in real life. The resulting toxic effects are often more than the simple sum of the effects of the individual compounds. It is unlikely that it will ever be possible to test all combinations. It is therefore highly desirable to improve or develop means for reasonably approximating predictions of interactions. In order to be valid and extrapolatable, these predictions are most promising if they are mechanism-based. Examples will be given for possibilities of mechanism-based predictions of interactions which exceed trivialities of simple increases by enzyme induction of enzymatic rates of a given biotransformation pathway leading to a toxic metabolite. Instead, examples will be provided where competition between various enzymes for shunting the same substrate into divergent pathways can lead to predictable dramatic changes in toxicity by shifting the metabolic routes under conditions of no significant changes of overall metabolism. Further examples are given on predictable interactions between chemicals which need bioactivation for exerting their toxicity and chemicals which effect hormonal status and other endogenous factors which in turn modify enzymes involved in the control of toxic metabolites.—Environ Health Perspect 102 (Suppl 9):5-9 (1994)

Key words: drug–drug interactions, interactions between foreign compounds (xenobiotics), protein phosphorylation, enzyme induction, enzyme inhibition, genotoxicity

Introduction

Interactions between xenobiotics based on enzyme inhibition can be very profound. Figure 1 shows an example of inhibition of the major microsomal epoxide hydrolase mEHb* at low concentration (0.3 μM) of 1,1,1-trichloropropene 2,3-oxide (2). At this concentration, no influences are known on any other enzyme contributing to the control of epoxides by either forming them or metabolizing them further. In the absence of this, modulator phenanthrene does not induce mutations in Salmonella typhimurium TA1537 to a measurable extent in agreement with the known noncarcinogenicity of the compound. However, 0.3 μM trichloropropene oxide leads to a pronounced mutagenicity. This concentration of the modulator led to an inhibition of mEHb (measured with the standard substrate benzo[a]pyrene 4,5-oxide which has a similar affinity to the enzyme as phenanthrene 9,10-oxide) of approximately 95%, that is to a lowering of the effective mEHb activity by a factor of roughly 20. Phylogenetic investigations had shown that the mEHb activities varied between individual vertebrate species by up to about 1000-fold (3). Thus, modulations by inhibitors far lower than variations in mEHb activities occurring between vertebrate species were sufficient to convert an apparent nonmutagen to a clearcut mutagen by sufficiently raising the steady state concentration of the responsible epoxide.

Interactions between Xenobiotics Based on Enzyme Induction

The well known mutagenic carcinogen benzo[a]pyrene is virtually nonmutagenic when activated by liver microsomes from rats which had not been pretreated with

---

This article was presented at the IV European ISSX Meeting on Toxicological Evaluation of Chemical Interactions: Relevance of Social, Environmental and Occupational Factors held 3-6 July 1992 in Bologna, Italy.

Address correspondence to Dr. F. Oesch, Department of Toxicology, University of Mainz, Obere Zahlbacher Strasse 67, D-6500 Mainz, Germany. Telephone 49 6131 231721. Fax 49 6131 230506.

---

Figure 1. Dose dependency of the mutagenic effect of phenanthrene after activation with liver microsomes from mice induced with Aroclor 1254 (500 mg/kg) for Salmonella typhimurium TA1537. * incubation without addition of an inhibitor for epoxide hydrolase. ⊕, 0.6 μl 1,1,1-trichloropropene 2,3-oxide in 10 μl dimethylsulfoxide was added to the incubation mixture. The horizontal lines indicate the range of numbers of colonies on plates without test compound (n = 8). Data from Buecker et al. (2), reproduced by permission of Mutation Research.
enzyme inducers (4). However, high mutagenicity is observed after induction by 3-methylcholanthrene. The dramatic difference is shown in Figure 2. The special practical importance is that in some cases such enzyme inductions may be a prerequisite for the mutagenicity and carcinogenicity to occur. This may be through induction by a compound different from the compound in question (interaction) or by a dose of the compound which is sufficient for induction (potential threshold of genotoxicity and carcinogenicity due to induction of constitutively not induced enzymes).

**Interactions between Xenobiotics Based on Shifts of Routes of Metabolism**

We incubated [14C]-benzo[α]pyrene with control and with trans-stilbene oxide (TSO)-induced rat liver microsomes and the metabolites were separated by HPLC (Table 1). Standard compounds and two different elution systems were used to characterize the metabolites. The results presented are derived from a separation using an acetonitrile-water gradient. Similar results were obtained using a methanol-water gradient with the exception that separation of the 4,5-epoxide peak from the 3,5-quinone peak was achieved with the acetonitrile-water but not with the methanol-water gradient. In addition, it was confirmed that metabolites, which were tentatively identified by their mobilities as dihydrodiols, were markedly reduced or disappeared when the inhibitor of mEH, 1,1,1-trichloropropene 2,3-oxide was present. As seen from Table 1, the total quantities of the metabolites was not significantly changed after TSO-treatment of the rats. However, a most remarkable shift of the metabolism occurred. The quantity of metabolites which were oxidized at the benzene ring (7,8-dihydroxy-7,8-dihydrobenzo[α]pyrene, 9,10-dihydroxy-9,10-dihydrobenzo[α]pyrene, 9-hydroxybenzo[α]pyrene) was greatly diminished, while far more K-region metabolites (4,5-dihydroxy-4,5-dihydrobenzo[α]pyrene, benzo[α]pyrene 4,5-oxide) were formed. The ratio between 7,8-dihydroxy-7,8-dihydrobenzo[α]pyrene and 4,5-dihydroxy-4,5-dihydrobenzo[α]pyrene was more than 20 times lower with TSO-induced microsomes than with control microsomes. Only insignificant changes were observed in the peaks containing the quinones and 3-hydroxybenzo[α]pyrene. As expected from the induction of mEH by TSO, a much higher percentage of the metabolically pro-

**Figure 2.** Activation of benzo[α]pyrene to a mutagen: potentiation by selective induction of monooxygenase. Benzo[α]pyrene and Salmonella typhimurium TA1537 bacteria were incubated with hepatic microsomes from control male Sprague-Dawley rats or from rats that had been pretreated intraperitoneally with 10 mg/kg of 3-methylcholanthrene in sunflower oil and killed 3 days later. Data from Oesch and Glatt (4); reproduced by permission of IARC publications.

| Radioactivity with mobility of the following reference compounds | Control rats | Trans-stilbene oxide treated rats | Ratio TSO-treated/control |
|---------------------------------------------------------------|--------------|---------------------------------|---------------------------|
| pmoles, mg protein x 20 min | % of metabolites | pmoles, mg protein x 20 min | % of metabolites | |
| 9,10-Dihydroxy-9,10-dihydrobenzo[α]pyrene | 1240 ± 90 | 13.5 | 460 ± 10 | 4.3 | 0.37 |
| 4,5-Dihydroxy-4,5-dihydrobenzo[α]pyrene | 430 ± 10 | 4.7 | 2670 ± 250 | 25.0 | 6.21 |
| 7,8-Dihydroxy-7,8-dihydrobenzo[α]pyrene | 330 ± 10 | 3.6 | 90 ± 30 | 0.8 | 0.27 |
| Benzo[α]pyrene 1,6-quinone and 3,6-quinone | 3690 ± 20 | 40.2 | 3750 ± 480 | 35.0 | 1.01 |
| Benzo[α]pyrene 4,5-oxide | 430 ± 90 | 4.7 | 760 ± 70 | 7.1 | 1.76 |
| 9-Hydroxybenzo[α]pyrene | 320 ± 10 | 3.5 | 120 ± 10 | 1.1 | 0.37 |
| 3-Hydroxybenzo[α]pyrene | 2190 ± 170 | 23.9 | 1840 ± 320 | 17.2 | 0.84 |
| Others | 550 ± 40 | 5.9 | 1030 ± 80 | 9.5 | 1.87 |
| Total | 9180 ± 390 | 100.0 | 10700 ± 1250 | 100.0 | 1.16 |

Data from Buecker et al. (5); reproduced by permission of Molecular Pharmacology. Ratio of metabolites present after 20 min incubation with microsomes from trans-stilbene oxide treated and control rats.
duced benzo[a]pyrene 4,5-oxide was converted to the corresponding dihydriodiol with TSO-induced microsomes.

Various doses of benzo[a]pyrene were activated by microsomes or postmitochondrial fractions to mutagens which were detected by the reversion of various his-Salmoneilla typhimurium strains. In general, induction by TSO, markedly decreased the mutagenicity of benzo[a]pyrene. The greatest reduction (by more than 90%) was observed when post-mitochondrial fractions and the strain TA100 were used (Figure 3A). Using microsomes, TSO treatment reduced the mutagenicity with TA100 by 65% (Figure 3B) and with TA98 by 40% (Figure 3C, round symbols). However, TSO treatment only slightly reduced the mutagenicity with TA1537 (Figure 3D, round symbols). The differences can be easily explained. The Salmonella assay is a backward mutation assay which requires specific mutations to reconstruct a functional his gene. Different his strains vary in their susceptibility to reversion by different benzo[a]pyrene metabolites. TA100 and TA98 are easily reverted by benzo[a]pyrene 7,8-dihydriodiol 9,10-oxides, and by benzo[a]pyrene 4,5-oxide. The strain TA1537 is less sensitive towards the 7,8-dihydriodiol 9,10-oxides but is highly sensitive to the 4,5-oxide (6). The greater decrease of mutagenicity by TSO induction with the strains which are sensitive to 7,8-dihydriodiol 9,10-oxides (TA100, TA98) when compared with a strain which is relatively insensitive towards these dihydriodiol epoxides (TA1537), suggests that the reduction of the mutagenicity is caused to a significant extent, by the decreased oxidation of benzo[a]pyrene at the benzo ring. The decreased benzo ring metabolism is accompanied by increased K-region metabolism, leading to the mutagenic benzo[a]pyrene 4,5-oxide, but mEHo, which is induced by TSO (7), can inactivate this mutagen (4,8).

The mEHo inhibitor 1,1,1-trichloropropene oxide (9) potentiated the mutagenic effects both with control and with TSO-induced microsomes (Figure 3C, 3D). This experiment could be performed only with TA98 and TA1537 since 1,1,1-trichloropropene oxide is too mutagenic with TA100 (10). With TA98, inhibition of mEHo increased the mutagenicity of benzo[a]pyrene activated with control microsomes about 3-fold, and with TSO-induced microsomes about 5-fold (Figure 3C). Also, with TA1537, inhibition of mEHo potentiated the mutagenicity more strongly when TSO-induced microsomes were used for the activation (Figure 3D). This shows the increased importance of mEHo for the inactivation of mutagenic benzo[a]pyrene metabolites after a shift of the metabolism to the K-region, since the K-region epoxide benzo[a]pyrene 5,6-oxide is an excellent substrate of mEHo, indeed is used as its diagnostic substrate (7).

Thus shifts in routes of metabolism due to interactions between xenobiotics can profoundly change their biological effects.

**Interactions between Xenobiotics Based on Posttranslational Modifications of Enzyme Proteins**

Overall organismic activities of xenobiotic-metabolizing enzymes may change by altering enzyme amount or specific activity by induction, repression, activation, or inhibition. Very widely studied is the contribution of induction, which is a relatively slow process requiring the biosynthesis of the enzyme protein. The possibility of a faster regulation of xenobiotic metabolism by posttranslational modification (e.g., by phosphorylation) of an already preexisting protein has only recently been attended. A central role in the metabolism of xenobiotics is played by the cytochrome P450-dependent monooxygenases.

Purified cAMP-dependent protein kinase (PKA) and purified calcium/phospholipid-dependent protein kinase (PKC) catalyze, donor- and acceptor-selectively,
the phosphorylation of some, but not all, purified cytochrome P450 isoenzymes, while the phosvitin/casein type II kinase was inactive for 13 cytochrome P450 isoenzymes investigated (11-14). In order to see whether this process also occurred in the intact cell, hepatocytes were exposed to 32P-orthophosphate to label the intracellular ATP pools. Hepatocytes were isolated from the liver of adult male Sprague-Dawley rats pretreated with phenobarbital in order to induce the cytochrome P450 isoenzymes 2B1 and 2B2 (cytochromes P450b and P450e, the two major phenobarbital-inducible cytochromes P450). Among the 13 investigated isoenzymes, these two had been the best substrates of PKA in the cell free system (12). In the absence of stimulation, the incorporation of radioactive phosphate into cytochromes P450 (isolated and purified after the incubation with 32P-orthophosphate) was very low. After stimulation by extracellular glucagon or by membrane permeating cAMP-derivatives (N6, O2'-dibutyryl-cAMP and 8-thiomiethyl-cAMP) a marked incorporation of 32P-phosphate into cytochrome P450 took place (15). Autoradiography of gel electrophoretically separated proteins from solubilized microsomes of these hepatocytes and of purified cytochromes P450 combined with visualization on Western blots by specific antibodies showed that four cytochromes P450 were phosphorylated, cytochromes P450 2B1 and 2B2, and two cytochromes P450 2B1-related proteins, one of them inducible by phenobarbital (15). Pyerin and Taniguchi (16) and Koch and Waxman (17) have also observed that the major phenobarbital-inducible cytochrome P450 is phosphorylated in the intact hepatocytes and in the whole animal (17) where phosphorylation took place in the liver in the absence of any exogenous stimulation and was increased by N6, O2'-dibutyryl-cAMP and theophyllin. Johansson et al. (14) reported on the phosphorylation of the ethanol-inducible cytochrome P450 isoenzyme 2E1 which was stimulated by cAMP analogues.

The phosphorylation of cytochromes P450 2B1 and 2B2 in intact hepatocytes led to a marked decrease in the microsomal monoxygenase activity towards substrates of these isoenzymes (18): The O-dealkylation of 7-pentoxyresorufin which represents a selective substrate of cytochromes P450 2B1 and 2B2 was markedly decreased; similarly, the metabolism of testosterone was markedly and regio- and stereo-selectively changed in those positions of the steroid molecule which are attacked by cytochromes P450 2B1 and 2B2. After treatment of the hepatocytes with the agents leading to phosphorylation of cytochromes 2B1 and 2B2 (cAMP derivatives), the 16β-hydroxylation of testosterone which is catalyzed by cytochromes P450 2B1 and 2B2 was decreased about 50% (18). The influence of the phosphorylation on the hydroxylation at the 16α-position was "diluted" (decreased about 30%) by those isoenzymes which in addition to the phosphorylated cytochromes P450 2B1 and 2B2 also catalyze this reaction, namely cytochromes P450 2C7 (P450f, immunologically crossreactive with cytochrome P450 2Bl, constitutive isoenzyme), cytochrome P450 2C11 (P450h, male specific testosterone 2α/(16α)-hydroxylase) and cytochrome P450g (male specific, strain-dependent) (19,20). Cytochromes P450 2B1 and 2B2 also catalyze the oxidation of the 17β-OH group of testosterone to a keto group (conversion to androstene-3,17-dione). However, this reaction is still less specific. Hence, the decrease in activity due to phosphorylation was even more "diluted" at this position and did not reach statistical significance. Janson et al. (21) reported that in a cell-free system phosphorylation of cytochrome P450 LM2 (the major phenobarbital-inducible cytochrome P450 in the rabbit liver, P450 2B4), inhibited the interaction of the latter with the former, leading to a loss of the stimulatory activity of cytochrome b5 to its reconstitution with cytochrome b5. Taniguchi et al. (22) reported that in a cell-free system the treatment of cytochrome P450 purified from the liver of a phenobarbital-treated rabbit with purified PKA leads to a destruction of cytochrome P450 to cytochrome P420. Johansson et al. (14) reported that in hepatocytes the agents which lead to an increase of phosphorylation of cytochrome P450 2El (glucagon and cAMP analogues) also lead to an increase in the degradation rate of cytochrome P450 2El. Agents which protected against the degradation also protected against phosphorylation. Based on these observations, the authors suggested that phosphorylation leads to a more rapid degradation of cytochrome P450 2E1. Thus, phosphorylation of cytochromes P450 may influence metabolism by modulating their activity as well as their levels.

The selective phosphorylation of defined cytochromes P450 by some defined protein kinases which themselves are under differential control in intact cells (and to the limited extent in which it has been investigated, also in animals) followed by highly selective and predictable changes in metabolic rates strongly suggests that interactions between xenobiotics may be expected on this level. Some expected interactions are listed in Figure 4. The issue gains further significance by our recent demonstration that these processes also occur in human tissue (Oesch-Bartlomowicz, Arens, Fahndrich, Vogel and Oesch, manuscript in preparation).

**Figure 4.** Interactions to be expected between compounds metabolized by cytochromes P450 phosphorylated by protein kinase A and compounds leading to increases in cAMP.

1. P450 2B1 substrates: Several cytostatic drugs (cyclophosphamide, ifosfamide), many barbiturates, several anticonvulsants.

2. P450 2E1 substrates: Many nitrosamines (dimethyl, diethyl, methyl, propyl, methyl, benzyl), vinyl halides, vinyl carbamate, urethane, acrylonitrile, styrene, benzene, many haloalkanes, chlorozoxazone.

3. Stimulants of adenylate cyclase: b-adrenergic stimulants, adrenalin or noradrenalin, or both.

4. Compounds leading to decrease of adenylate cyclase activity: b-blockers.

5. Phosphodiesterase inhibitors: methylxanthes (theophylline, caffeine).

**Conclusions**

Interactions between xenobiotics may profoundly influence their toxic effects. The permutations of possible interactions are expected to lead to an infinite number of conceivable situations which may never be amenable to individual investigation. Development of possibilities for reasonable approximations and predictions are therefore desirable. They may be most effective if the underlying considerations are mechanism-based. This overview summarizes a few possibilities such as enzyme inhibition, enzyme induction, shift of routes of metabolism, and postranslational modification of enzymes.
REFERENCES

1. Timms C, Oesch F, Schladt L, Woerner, W. Multiple forms of epoxide hydrolase. In: Proceedings of the 9th International Congress of Pharmacology. London:1984 (Mitchell JF, Paton W, Turner T, eds). Macmillan, London:1984, 231–237.

2. Buecker M, Glatt HR, Platt KL, Avnir D, Irrah Y, Blum J, Oesch F. Mutagenicity of phenanthrene and phenanthrene K-region derivatives. Mutat Res 66: 337–348 (1979).

3. Walker CH, Bentley P, Oesch F. Phyllogenetic distribution of epoxide hydratase in different vertebrate species, strains and tissues measured using three substrates. Biochem Biophys Acta 539: 427–434 (1978).

4. Oesch F, Glatt HR. Evaluation of the relative importance of various enzymes involved in the control of mutagenic and cytotoxic metabolites. In: Tests in Chemical Carcinogenesis (Montesano R, Bartsch H, Tomatis L, eds). IARC Scientific Publications No. 12. Lyon:International Agency for Research on Cancer, 1976:255–274.

5. Buecker M, Golan M, Schmassmann HU, Glatt HR, Staiecki P, Oesch F. The epoxide hydratase inducer trans-stilbene oxide shifts the metabolic epoxidation of benzo[a]pyrene from the bay- to the K-region and reduces its mutagenicity. Mol Pharmacol 16: 656–666 (1979).

6. Bentley P, Oesch F, Glatt HR. Dual role of epoxide hydratase in both activation and inactivation. Arch Toxicol 39: 65–75 (1977).

7. Schmassmann HU, Oesch F. Trans-stilbene oxide: selective inducer of rat liver epoxide hydratase. Mol Pharmacol 14:834–847 (1978).

8. Wood AW, Levin W, Lu AYH, Yagi H, Hernandez O, Jerina DM, Conney AH. Metabolism of benzo[a]pyrene and benzo[a]pyrene derivatives to mutagenic products by highly purified hepatic microsomal enzymes. J Biol Chem 251:4882–4890 (1976).

9. Oesch F, Kaubisch N, Jerina DM, Daly J. Hepatic epoxide hydrase: structure-activity relationships for substrates and inhibitors. Biochemistry 10:4858–4866 (1971).

10. Glatt HR, Olsson A, Agurell S, Oesch F. Delta1-tetrahydrocannabinol and 1α,20-epoxyhexahydrocannabinol: Mutagenicity investigation in the Ames test. Mutat Res 66: 329–335 (1979).

11. Pyerin W, Wolf CR, Kinzel V, Kübler D, Oesch F. Phosphorylation of cytochrome P-450-dependent monoxygenase components. Carcinogenesis 4:573–576 (1983).

12. Pyerin W, Taniguchi H, Horn F, Oesch F, Amelizad Z, Friedberg T, Wolf CR. Isoenzyme-specific phosphorylation of cytochromes P-450 and other drug metabolizing enzymes. Biochem Biophys Res Commun 142:885–892 (1987).

13. Epstein PM, Curti M, Jansson I, Huang CK, Schenkmann JB. Phosphorylation of cytochrome b5. Arch Biochem Biophys 271:424–432 (1989).

14. Johanson J, Elisson E, Johanson A, Hagbjörk AL, Lindros K, Ingelman-Sundberg M. Mechanism of ethanol- and acetone-dependent induction of cytochromes P-450. In: Proceeding of the 6th International Conference on Biochemistry and Biophysics of Cytochrome P-450, Vienna, 1988 (Schuster I, ed). Taylor and Francis, London, 1989:592–595.

15. Bartlomowicz B, Waxman DJ, Utesch D, Oesch F, Friedberg T. Phosphorylation of carcinogen metabolizing enzymes: regulation of the phosphorylation status of the major phenobarbital inducible cytochromes P-450 in hepatocytes. Carcinogenesis 10:225–228 (1989).

16. Pyerin W, Taniguchi H. Phosphorylation of hepatic phenobarbital-inducible cytochrome P-450. EMBO J 8:3003–3010 (1989).

17. Koch JA, Waxman DJ. Posttranslational modification of hepatic cytochrome P-450. Phosphorylation of phenobarbital-inducible P-450 forms PB-4 (IIBl) and PB-5 (IIb2) in isolated rat hepatocytes and in vivo. Biochemistry 28:3145–3152 (1989).

18. Bartlomowicz B, Friedberg T, Utesch D, Molitor E, Platt KL, and Oesch F. Regio- and stereoselective regulation of monooxygenase activities by isoenzyme-selective phosphorylation of cytochrome P450. Biochem Biophys Res Commun 160: 46–52 (1989).

19. Levin W, Thomas PE, Reik LM, Wood AW, Ryan DE. Multiplicity and functional diversity of rat hepatic microsomal cytochrome P-450 isozymes. In: Proceedings of the IUPHAR 9th International Congress of Pharmacology, London, 1984 (Mitchell JF, Paton W, Turner T, eds). Macmillan, London, 1984:203–209.

20. Waxman DJ. Interactions of hepatic cytochromes P-450 with steroid hormones: Regioselectivity and stereospecificity of steroid hydroxylation and hormonal regulation of rat P-450 enzyme expression. Biochem Pharmacol 37:71–84 (1988).

21. Jansson I, Epstein PM, Bains S, Schenkmann JB. Inverse relationship between cytochrome P-450 phosphorylation and complexation with cytochrome b5. Arch Biochem Biophys 259:441–448 (1987).

22. Taniguchi H, Pyerin W, Stier A. Conversion of hepatic microsomal cytochrome P-450 to P-420 upon phosphorylation by cyclic AMP dependent protein kinase. Biochem Pharmacol 34:1835–1837 (1985).